ApnoMed
Private Company
Funding information not available
Overview
ApnoMed is a U.S.-based medical technology company founded in 2008, operating at the intersection of respiratory health and dental sleep medicine. It has developed a proprietary platform and provider network to diagnose, manage, and treat airway disorders, with a strong emphasis on its ApnoDent® oral appliance and teledontic/telegnathic procedures. The company leverages over 20 years of clinical evidence, claims a 95% success rate, and differentiates itself through rigorous provider certification and a holistic, multidisciplinary care model. It appears to be a commercial-stage, private company generating revenue through its platform and provider services.
Technology Platform
A comprehensive platform combining proprietary medical devices (e.g., ApnoDent® hybrid mandibular advancement device) with digital/clinical protocols for teledontics/telegnathics. It connects patients with a certified multidisciplinary provider network trained in airway-centered care, offering solutions from pediatric prevention to advanced adult treatment.
Opportunities
Risk Factors
Competitive Landscape
ApnoMed competes in the oral appliance therapy market against large players like SomnoMed and ProSomnus, as well as numerous dental labs. It differentiates through its hybrid device design (targeting TMJ and OSA concurrently) and its integrated platform model. In pediatric airway, it faces competition from orthodontic-focused practices and early-intervention programs, but its teledontic protocol and founder's publication record provide a niche advantage.